Anika to Participate in Two Investor Events in May 2019

- Deutsche Bank 44th Annual Health Care Conference on Tuesday, May 7, 2019 at The InterContinental Hotel in Boston. - Singular Research Spring Select Web Call on Thursday, May 30, 2019.

Logo
May 6, 2019 12:30 UTC

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that the Company will participate in the following two investor events in May:

  • Deutsche Bank 44th Annual Health Care Conference on Tuesday, May 7, 2019 at The InterContinental Hotel in Boston.
  • Singular Research Spring Select Web Call on Thursday, May 30, 2019.

A live audio webcast of the Singular Research Spring Select Web Call may be accessed via the Investor Relations section of Anika’s website at www.anikatherapeutics.com. An audio archive of the presentation also will be available on the website.

About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

Contacts

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer

For Media Inquiries:
W2O Group
Sonal Vasudev, 917-523-1418
sonal@w2ogroup.com

Source: Anika Therapeutics, Inc.

MORE ON THIS TOPIC